BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//TrialSonar//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:TrialSonar · $JNJ readouts
X-WR-CALDESC:Clinical-trial primary completion dates from ClinicalTrials.go
 v\, refreshed nightly by TrialSonar. Not investment advice.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07230860-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20261119
DTEND;VALUE=DATE:20261120
SUMMARY:READY-AD readout (P2) · Janssen Research & Development\, LLC $JNJ
DESCRIPTION:A Study of JNJ-95597528 in Participants With Moderate to Severe
  Atopic Dermatitis\n\nPrimary completion date: 2026-11-19 (estimated)\nPha
 se 2 · Immuno · Dermatitis\, Atopic\nEnrollment: 189 · Sites: 62\n\nPri
 mary completion = last participant's primary-endpoint data collected\; top
 line results usually follow weeks to months later. Sponsor-reported\, ofte
 n an estimate. Not investment advice.\n\nhttps://datacutoff.com/ra
 dar.html?nct=NCT07230860\nhttps://clinicaltrials.gov/study/NCT07230860
URL:https://datacutoff.com/radar.html?nct=NCT07230860
CATEGORIES:Immuno,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03767244-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:PROTEUS readout (P3) · Janssen Research & Development\, LLC $JNJ
DESCRIPTION:A Study of Apalutamide in Participants With High-Risk\, Localiz
 ed or Locally Advanced Prostate Cancer Who Are Candidates for Radical Pros
 tatectomy\n\nPrimary completion date: 2026-12-01 (estimated)\nOriginally p
 lanned: 2024-04-22 (+31.3 months)\nPhase 3 · Oncology · Prostatic Neopla
 sms\nEnrollment: 2517 · Sites: 203\n\nPrimary completion = last participa
 nt's primary-endpoint data collected\; topline results usually follow week
 s to months later. Sponsor-reported\, often an estimate. Not investment ad
 vice.\n\nhttps://datacutoff.com/radar.html?nct=NCT03767244\nhttps:
 //clinicaltrials.gov/study/NCT03767244
URL:https://datacutoff.com/radar.html?nct=NCT03767244
CATEGORIES:Oncology,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05757869-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20261208
DTEND;VALUE=DATE:20261209
SUMMARY:LIBREXIA-AF readout (P3) · Janssen Research & Development\, LLC $J
 NJ
DESCRIPTION:A Study of Milvexian Versus Apixaban in Participants With Atria
 l Fibrillation\n\nPrimary completion date: 2026-12-08 (estimated)\nOrigina
 lly planned: 2027-03-05 (-2.9 months)\nPhase 3 · Cardio-Met · Atrial Fib
 rillation\nEnrollment: 20284 · Sites: 1052\n\nPrimary completion = last p
 articipant's primary-endpoint data collected\; topline results usually fol
 low weeks to months later. Sponsor-reported\, often an estimate. Not inves
 tment advice.\n\nhttps://datacutoff.com/radar.html?nct=NCT05757869
 \nhttps://clinicaltrials.gov/study/NCT05757869
URL:https://datacutoff.com/radar.html?nct=NCT05757869
CATEGORIES:Cardio-Met,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05327114-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20261215
DTEND;VALUE=DATE:20261216
SUMMARY:Nipocalimab readout (P2/3) · Janssen Research & Development\, LLC 
 $JNJ
DESCRIPTION:Efficacy and Safety Study of Nipocalimab for Adults With Chroni
 c Inflammatory Demyelinating Polyneuropathy (CIDP)\n\nPrimary completion d
 ate: 2026-12-15 (estimated)\nOriginally planned: 2026-05-11 (+7.2 months)\
 nPhase 2/3 · Neuro · Polyradiculoneuropathy\, Chronic Inflammatory Demye
 linating\nEnrollment: 201 · Sites: 120\n\nPrimary completion = last parti
 cipant's primary-endpoint data collected\; topline results usually follow 
 weeks to months later. Sponsor-reported\, often an estimate. Not investmen
 t advice.\n\nhttps://datacutoff.com/radar.html?nct=NCT05327114\nht
 tps://clinicaltrials.gov/study/NCT05327114
URL:https://datacutoff.com/radar.html?nct=NCT05327114
CATEGORIES:Neuro,Phase 2/3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06544616-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20261222
DTEND;VALUE=DATE:20261223
SUMMARY:Reτain readout (P2) · Janssen Pharmaceutica N.V.\, Belgium $JNJ
DESCRIPTION:A Study of JNJ-64042056 in Participants With Preclinical Alzhei
 mer's Disease\n\nPrimary completion date: 2026-12-22 (estimated)\nOriginal
 ly planned: 2031-07-17 (-54.8 months)\nPhase 2 · Neuro · Alzheimer Disea
 se\nEnrollment: 55 · Sites: 90\n\nPrimary completion = last participant's
  primary-endpoint data collected\; topline results usually follow weeks to
  months later. Sponsor-reported\, often an estimate. Not investment advice
 .\n\nhttps://datacutoff.com/radar.html?nct=NCT06544616\nhttps://cl
 inicaltrials.gov/study/NCT06544616
URL:https://datacutoff.com/radar.html?nct=NCT06544616
CATEGORIES:Neuro,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04658862-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:SunRISe-2 readout (P3) · Janssen Research & Development\, LLC $JNJ
DESCRIPTION:A Study of TAR-200 in Combination With Cetrelimab Versus Concur
 rent Chemoradiotherapy in Participants With Muscle-invasive Bladder Cancer
  (MIBC) of the Bladder\n\nPrimary completion date: 2026-12-30 (estimated)\
 nPhase 3 · Oncology · Urinary Bladder Neoplasms\nEnrollment: 518 · Site
 s: 290\n\nPrimary completion = last participant's primary-endpoint data co
 llected\; topline results usually follow weeks to months later. Sponsor-re
 ported\, often an estimate. Not investment advice.\n\nhttps://trialsonar.n
 etlify.app/radar.html?nct=NCT04658862\nhttps://clinicaltrials.gov/study/NC
 T04658862
URL:https://datacutoff.com/radar.html?nct=NCT04658862
CATEGORIES:Oncology,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06559306-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:Seltorexant readout (P3) · Janssen Research & Development\, LLC $J
 NJ
DESCRIPTION:Phase 3 Study of Adjunctive Treatment With Seltorexant in Adult
  and Elderly Participants With Major Depressive Disorder and Insomnia Symp
 toms\n\nPrimary completion date: 2026-12-30 (estimated)\nPhase 3 · Neuro 
 · Depressive Disorder\, Major\nEnrollment: 752 · Sites: 205\n\nPrimary c
 ompletion = last participant's primary-endpoint data collected\; topline r
 esults usually follow weeks to months later. Sponsor-reported\, often an e
 stimate. Not investment advice.\n\nhttps://datacutoff.com/radar.ht
 ml?nct=NCT06559306\nhttps://clinicaltrials.gov/study/NCT06559306
URL:https://datacutoff.com/radar.html?nct=NCT06559306
CATEGORIES:Neuro,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT01804686-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:CAN3001 readout (P3) · Janssen Research & Development\, LLC $JNJ
DESCRIPTION:A Long-term Extension Study of PCI-32765 (Ibrutinib)\n\nPrimary
  completion date: 2026-12-31 (estimated)\nOriginally planned: 2016-01 (+13
 2.0 months)\nPhase 3 · Oncology · Chronic Lymphocytic Leukemia\, Small L
 ymphocytic Lymphoma\, Mantle Cell Lymphoma\nEnrollment: 539 · Sites: 156\
 n\nPrimary completion = last participant's primary-endpoint data collected
 \; topline results usually follow weeks to months later. Sponsor-reported\
 , often an estimate. Not investment advice.\n\nhttps://trialsonar.netlify.
 app/radar.html?nct=NCT01804686\nhttps://clinicaltrials.gov/study/NCT018046
 86
URL:https://datacutoff.com/radar.html?nct=NCT01804686
CATEGORIES:Oncology,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06741969-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20270204
DTEND;VALUE=DATE:20270205
SUMMARY:DAFFODIL readout (P3) · Janssen Research & Development\, LLC $JNJ
DESCRIPTION:Nipocalimab in Moderate to Severe Sjogren's Disease\n\nPrimary 
 completion date: 2027-02-04 (estimated)\nOriginally planned: 2028-01-01 (-
 10.9 months)\nPhase 3 · Immuno · Sjogrens Syndrome\nEnrollment: 655 · S
 ites: 254\n\nPrimary completion = last participant's primary-endpoint data
  collected\; topline results usually follow weeks to months later. Sponsor
 -reported\, often an estimate. Not investment advice.\n\nhttps://trialsona
 r.netlify.app/radar.html?nct=NCT06741969\nhttps://clinicaltrials.gov/study
 /NCT06741969
URL:https://datacutoff.com/radar.html?nct=NCT06741969
CATEGORIES:Immuno,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06260163-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20270210
DTEND;VALUE=DATE:20270211
SUMMARY:QUASAR Jr readout (P3) · Janssen Research & Development\, LLC $JNJ
DESCRIPTION:A Study of Guselkumab in Pediatric Participants With Moderately
  to Severely Active Ulcerative Colitis\n\nPrimary completion date: 2027-02
 -10 (estimated)\nOriginally planned: 2028-05-22 (-15.3 months)\nPhase 3 ·
  GI·Renal·Heme · Colitis\, Ulcerative\nEnrollment: 112 · Sites: 61\n\n
 Primary completion = last participant's primary-endpoint data collected\; 
 topline results usually follow weeks to months later. Sponsor-reported\, o
 ften an estimate. Not investment advice.\n\nhttps://datacutoff.com
 /radar.html?nct=NCT06260163\nhttps://clinicaltrials.gov/study/NCT06260163
URL:https://datacutoff.com/radar.html?nct=NCT06260163
CATEGORIES:GI·Renal·Heme,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06807424-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20270210
DTEND;VALUE=DATE:20270211
SUMMARY:ICONIC-PsA 2 readout (P3) · Janssen Research & Development\, LLC $
 JNJ
DESCRIPTION:A Study to Evaluate the Efficacy and Safety of Icotrokinra (JNJ
 -77242113) in Biologic-experienced and Biologic-naive Participants With Ac
 tive Psoriatic Arthritis\n\nPrimary completion date: 2027-02-10 (estimated
 )\nPhase 3 · Immuno · Arthritis\, Psoriatic\nEnrollment: 813 · Sites: 2
 36\n\nPrimary completion = last participant's primary-endpoint data collec
 ted\; topline results usually follow weeks to months later. Sponsor-report
 ed\, often an estimate. Not investment advice.\n\nhttps://trialsonar.netli
 fy.app/radar.html?nct=NCT06807424\nhttps://clinicaltrials.gov/study/NCT068
 07424
URL:https://datacutoff.com/radar.html?nct=NCT06807424
CATEGORIES:Immuno,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04133636-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20270226
DTEND;VALUE=DATE:20270227
SUMMARY:CARTITUDE-2 readout (P2) · Janssen Research & Development\, LLC $J
 NJ
DESCRIPTION:A Study of JNJ-68284528\, a Chimeric Antigen Receptor T Cell (C
 AR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Partici
 pants With Multiple Myeloma\n\nPrimary completion date: 2027-02-26 (estima
 ted)\nOriginally planned: 2022-04-12 (+58.5 months)\nPhase 2 · Oncology 
 · Multiple Myeloma\nEnrollment: 208 · Sites: 47\n\nPrimary completion = 
 last participant's primary-endpoint data collected\; topline results usual
 ly follow weeks to months later. Sponsor-reported\, often an estimate. Not
  investment advice.\n\nhttps://datacutoff.com/radar.html?nct=NCT04
 133636\nhttps://clinicaltrials.gov/study/NCT04133636
URL:https://datacutoff.com/radar.html?nct=NCT04133636
CATEGORIES:Oncology,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05347095-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20270325
DTEND;VALUE=DATE:20270326
SUMMARY:FUZION CD readout (P3) · Janssen-Cilag Ltd. $JNJ
DESCRIPTION:A Study of Guselkumab in Participants With Fistulizing\, Perian
 al Crohn's Disease\n\nPrimary completion date: 2027-03-25 (estimated)\nOri
 ginally planned: 2025-03-15 (+24.3 months)\nPhase 3 · GI·Renal·Heme · 
 Fistulizing Crohns Disease\, Perianal Crohns Disease\nEnrollment: 288 · S
 ites: 154\n\nPrimary completion = last participant's primary-endpoint data
  collected\; topline results usually follow weeks to months later. Sponsor
 -reported\, often an estimate. Not investment advice.\n\nhttps://trialsona
 r.netlify.app/radar.html?nct=NCT05347095\nhttps://clinicaltrials.gov/study
 /NCT05347095
URL:https://datacutoff.com/radar.html?nct=NCT05347095
CATEGORIES:GI·Renal·Heme,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06120140-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:COCOON readout (P2) · Janssen Research & Development\, LLC $JNJ
DESCRIPTION:Enhanced Dermatological Care to Reduce Rash and Paronychia in E
 pidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer 
 (NSCLC) Treated First-line With Amivantama…\n\nPrimary completion date: 
 2027-05-31 (estimated)\nOriginally planned: 2025-04-03 (+25.9 months)\nPha
 se 2 · Oncology · Carcinoma\, Non-Small-Cell Lung\nEnrollment: 305 · Si
 tes: 93\n\nPrimary completion = last participant's primary-endpoint data c
 ollected\; topline results usually follow weeks to months later. Sponsor-r
 eported\, often an estimate. Not investment advice.\n\nhttps://trialsonar.
 netlify.app/radar.html?nct=NCT06120140\nhttps://clinicaltrials.gov/study/N
 CT06120140
URL:https://datacutoff.com/radar.html?nct=NCT06120140
CATEGORIES:Oncology,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06408935-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20270608
DTEND;VALUE=DATE:20270609
SUMMARY:REASON readout (P3) · Janssen-Cilag Ltd. $JNJ
DESCRIPTION:Transmural Healing and Disease-Modifying Effect of Guselkumab i
 n Crohn's Disease Patients\n\nPrimary completion date: 2027-06-08 (estimat
 ed)\nPhase 3 · GI·Renal·Heme · Crohn's Disease\nEnrollment: 120 · Sit
 es: 84\n\nPrimary completion = last participant's primary-endpoint data co
 llected\; topline results usually follow weeks to months later. Sponsor-re
 ported\, often an estimate. Not investment advice.\n\nhttps://trialsonar.n
 etlify.app/radar.html?nct=NCT06408935\nhttps://clinicaltrials.gov/study/NC
 T06408935
URL:https://datacutoff.com/radar.html?nct=NCT06408935
CATEGORIES:GI·Renal·Heme,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07266441-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20270614
DTEND;VALUE=DATE:20270615
SUMMARY:TRIlogy-3 readout (P2) · Janssen Research & Development\, LLC $JNJ
DESCRIPTION:A Study of JNJ-79635322 in Participants With Relapsed or Refrac
 tory Multiple Myeloma\n\nPrimary completion date: 2027-06-14 (estimated)\n
 Phase 2 · Oncology · Multiple Myeloma\nEnrollment: 168 · Sites: 71\n\nP
 rimary completion = last participant's primary-endpoint data collected\; t
 opline results usually follow weeks to months later. Sponsor-reported\, of
 ten an estimate. Not investment advice.\n\nhttps://datacutoff.com/
 radar.html?nct=NCT07266441\nhttps://clinicaltrials.gov/study/NCT07266441
URL:https://datacutoff.com/radar.html?nct=NCT07266441
CATEGORIES:Oncology,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07321873-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20270628
DTEND;VALUE=DATE:20270629
SUMMARY:VELOTA readout (P2) · Janssen Research & Development\, LLC $JNJ
DESCRIPTION:A Study to Evaluate the Efficacy and Safety of JNJ-88545223 for
  the Treatment of Participants With Active Psoriatic Arthritis\n\nPrimary 
 completion date: 2027-06-28 (estimated)\nPhase 2 · Immuno · Arthritis\, 
 Psoriatic\nEnrollment: 157 · Sites: 75\n\nPrimary completion = last parti
 cipant's primary-endpoint data collected\; topline results usually follow 
 weeks to months later. Sponsor-reported\, often an estimate. Not investmen
 t advice.\n\nhttps://datacutoff.com/radar.html?nct=NCT07321873\nht
 tps://clinicaltrials.gov/study/NCT07321873
URL:https://datacutoff.com/radar.html?nct=NCT07321873
CATEGORIES:Immuno,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04634552-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:MonumenTAL-1 readout (P2) · Janssen Research & Development\, LLC $
 JNJ
DESCRIPTION:A Study of Talquetamab in Participants With Relapsed or Refract
 ory Multiple Myeloma\n\nPrimary completion date: 2027-06-30 (estimated)\nO
 riginally planned: 2023-09-27 (+45.1 months)\nPhase 2 · Oncology · Hemat
 ological Malignancies\nEnrollment: 510 · Sites: 78\n\nPrimary completion 
 = last participant's primary-endpoint data collected\; topline results usu
 ally follow weeks to months later. Sponsor-reported\, often an estimate. N
 ot investment advice.\n\nhttps://datacutoff.com/radar.html?nct=NCT
 04634552\nhttps://clinicaltrials.gov/study/NCT04634552
URL:https://datacutoff.com/radar.html?nct=NCT04634552
CATEGORIES:Oncology,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05265273-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Nipocalimab readout (P2/3) · Janssen Research & Development\, LLC 
 $JNJ
DESCRIPTION:A Study of Nipocalimab in Children Aged 2 to Less Than 18 Years
  With Generalized Myasthenia Gravis\n\nPrimary completion date: 2027-06-30
  (estimated)\nOriginally planned: 2025-03-19 (+27.4 months)\nPhase 2/3 · 
 Oncology · Myasthenia Gravis\nEnrollment: 12 · Sites: 19\n\nPrimary comp
 letion = last participant's primary-endpoint data collected\; topline resu
 lts usually follow weeks to months later. Sponsor-reported\, often an esti
 mate. Not investment advice.\n\nhttps://datacutoff.com/radar.html?
 nct=NCT05265273\nhttps://clinicaltrials.gov/study/NCT05265273
URL:https://datacutoff.com/radar.html?nct=NCT05265273
CATEGORIES:Oncology,Phase 2/3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05455320-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20270730
DTEND;VALUE=DATE:20270731
SUMMARY:MonumenTAL-3 readout (P3) · Janssen Research & Development\, LLC $
 JNJ
DESCRIPTION:A Study Comparing Talquetamab in Combination With Daratumumab o
 r in Combination With Daratumumab and Pomalidomide Versus Daratumumab in C
 ombination With Pomalidomide and Dexametha…\n\nPrimary completion date: 
 2027-07-30 (estimated)\nOriginally planned: 2026-02-06 (+17.7 months)\nPha
 se 3 · Oncology · Multiple Myeloma\nEnrollment: 864 · Sites: 216\n\nPri
 mary completion = last participant's primary-endpoint data collected\; top
 line results usually follow weeks to months later. Sponsor-reported\, ofte
 n an estimate. Not investment advice.\n\nhttps://datacutoff.com/ra
 dar.html?nct=NCT05455320\nhttps://clinicaltrials.gov/study/NCT05455320
URL:https://datacutoff.com/radar.html?nct=NCT05455320
CATEGORIES:Oncology,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05912517-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20270805
DTEND;VALUE=DATE:20270806
SUMMARY:AZALEA readout (P3) · Janssen Research & Development\, LLC $JNJ
DESCRIPTION:A Study of Nipocalimab in Pregnancies at Risk for Severe Hemoly
 tic Disease of the Fetus and Newborn (HDFN)\n\nPrimary completion date: 20
 27-08-05 (estimated)\nPhase 3 · Other · Hemolytic Disease of the Fetus a
 nd Newborn\nEnrollment: 120 · Sites: 69\n\nPrimary completion = last part
 icipant's primary-endpoint data collected\; topline results usually follow
  weeks to months later. Sponsor-reported\, often an estimate. Not investme
 nt advice.\n\nhttps://datacutoff.com/radar.html?nct=NCT05912517\nh
 ttps://clinicaltrials.gov/study/NCT05912517
URL:https://datacutoff.com/radar.html?nct=NCT05912517
CATEGORIES:Other,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05498428-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20270817
DTEND;VALUE=DATE:20270818
SUMMARY:PALOMA-2 readout (P2) · Janssen Research & Development\, LLC $JNJ
DESCRIPTION:A Study of Amivantamab in Participants With Advanced or Metasta
 tic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated
  Non-Small Cell Lung Cancer\n\nPrimary completion date: 2027-08-17 (estima
 ted)\nOriginally planned: 2024-05-21 (+38.9 months)\nPhase 2 · Oncology 
 · Carcinoma\, Non-small-Cell Lung\nEnrollment: 520 · Sites: 110\n\nPrima
 ry completion = last participant's primary-endpoint data collected\; topli
 ne results usually follow weeks to months later. Sponsor-reported\, often 
 an estimate. Not investment advice.\n\nhttps://datacutoff.com/rada
 r.html?nct=NCT05498428\nhttps://clinicaltrials.gov/study/NCT05498428
URL:https://datacutoff.com/radar.html?nct=NCT05498428
CATEGORIES:Oncology,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06550895-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20270826
DTEND;VALUE=DATE:20270827
SUMMARY:MonumenTAL-8 readout (P2) · Janssen Research & Development\, LLC $
 JNJ
DESCRIPTION:A Study of Ciltacabtagene Autoleucel and Talquetamab for the Tr
 eatment of Participants With High-Risk Multiple Myeloma\n\nPrimary complet
 ion date: 2027-08-26 (estimated)\nOriginally planned: 2026-10-16 (+10.3 mo
 nths)\nPhase 2 · Oncology · Multiple Myeloma\nEnrollment: 11 · Sites: 9
 \n\nPrimary completion = last participant's primary-endpoint data collecte
 d\; topline results usually follow weeks to months later. Sponsor-reported
 \, often an estimate. Not investment advice.\n\nhttps://trialsonar.netlify
 .app/radar.html?nct=NCT06550895\nhttps://clinicaltrials.gov/study/NCT06550
 895
URL:https://datacutoff.com/radar.html?nct=NCT06550895
CATEGORIES:Oncology,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07217587-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20270928
DTEND;VALUE=DATE:20270929
SUMMARY:EPIC readout (P3) · Janssen Research & Development\, LLC $JNJ
DESCRIPTION:Comparative Efficacy of Nipocalimab and Efgartigimod in Partici
 pants With Generalized Myasthenia Gravis\n\nPrimary completion date: 2027-
 09-28 (estimated)\nPhase 3 · Oncology · Myasthenia Gravis\nEnrollment: 1
 15 · Sites: 31\n\nPrimary completion = last participant's primary-endpoin
 t data collected\; topline results usually follow weeks to months later. S
 ponsor-reported\, often an estimate. Not investment advice.\n\nhttps://tri
 alsonar.netlify.app/radar.html?nct=NCT07217587\nhttps://clinicaltrials.gov
 /study/NCT07217587
URL:https://datacutoff.com/radar.html?nct=NCT07217587
CATEGORIES:Oncology,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05092269-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20270929
DTEND;VALUE=DATE:20270930
SUMMARY:UNITED readout (P3) · Janssen Research & Development\, LLC $JNJ
DESCRIPTION:A Long-term Extension Study of Ustekinumab in Pediatric Partici
 pants\n\nPrimary completion date: 2027-09-29 (estimated)\nPhase 3 · GI·R
 enal·Heme · Crohn Disease\, Colitis\, Ulcerative\, Arthritis\, Psoriatic
 \nEnrollment: 159 · Sites: 48\n\nPrimary completion = last participant's 
 primary-endpoint data collected\; topline results usually follow weeks to 
 months later. Sponsor-reported\, often an estimate. Not investment advice.
 \n\nhttps://datacutoff.com/radar.html?nct=NCT05092269\nhttps://cli
 nicaltrials.gov/study/NCT05092269
URL:https://datacutoff.com/radar.html?nct=NCT05092269
CATEGORIES:GI·Renal·Heme,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05923073-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20271027
DTEND;VALUE=DATE:20271028
SUMMARY:MACARONI-23 readout (P3) · Janssen Research & Development\, LLC $J
 NJ
DESCRIPTION:A Study of Guselkumab in Pediatric Participants With Moderately
  to Severely Active Crohn's Disease\n\nPrimary completion date: 2027-10-27
  (estimated)\nPhase 3 · GI·Renal·Heme · Crohn's Disease\nEnrollment: 1
 20 · Sites: 85\n\nPrimary completion = last participant's primary-endpoin
 t data collected\; topline results usually follow weeks to months later. S
 ponsor-reported\, often an estimate. Not investment advice.\n\nhttps://tri
 alsonar.netlify.app/radar.html?nct=NCT05923073\nhttps://clinicaltrials.gov
 /study/NCT05923073
URL:https://datacutoff.com/radar.html?nct=NCT05923073
CATEGORIES:GI·Renal·Heme,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07225946-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20271119
DTEND;VALUE=DATE:20271120
SUMMARY:KLK2-PASenger readout (P3) · Janssen Research & Development\, LLC 
 $JNJ
DESCRIPTION:A Study of Pasritamig With Docetaxel Versus Docetaxel in Partic
 ipants With Metastatic Castration-Resistant Prostate Cancer\n\nPrimary com
 pletion date: 2027-11-19 (estimated)\nPhase 3 · Oncology · Prostatic Neo
 plasms\, Castration-Resistant\nEnrollment: 800 · Sites: 165\n\nPrimary co
 mpletion = last participant's primary-endpoint data collected\; topline re
 sults usually follow weeks to months later. Sponsor-reported\, often an es
 timate. Not investment advice.\n\nhttps://datacutoff.com/radar.htm
 l?nct=NCT07225946\nhttps://clinicaltrials.gov/study/NCT07225946
URL:https://datacutoff.com/radar.html?nct=NCT07225946
CATEGORIES:Oncology,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
